Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Clinical trial NCT00660504 · COMPLETED
Trial details
- NCT number
- NCT00660504
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2008-04-01
- Primary completion
- 2012-02-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.